SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SSgA Active Trust - State Street SPDR S&P 500 ETF Trust

The SPDR S&P 500 ETF Trust is experiencing high pre-market volatility as investors weigh geopolitical tensions in the Middle East and rising oil prices against upcoming Federal Reserve policy updates. The community is sharply divided, with active discussions focusing on whether the recent overnight price pumps are sustainable market manipulation or a prelude to a significant pullback ahead of key economic data.

SoFi Technologies, Inc. is a financial service platform, which engages in the provision of student loan refinancing options to the private student loan market. It operates through the following segments: Lending, Technology Platform, and Financial Services. The Lending segment offers personal loans, student loans, home loan products, and related servicing activities. The Technology Platform segment focuses on technology products and solutions revenue. The Financial Services segment includes the SoFi Money product, SoFi Invest product, SoFi Credit Card product, SoFi Relay personal finance management product, and other financial services such as lead generation and content for other financial services institutions. The company was founded in 2011 and is headquartered in San Francisco, CA.

SoFi Technologies Inc

SoFi Technologies is trending after a sharp volatility spike triggered by a critical short-seller report from Muddy Waters, which alleged accounting discrepancies and unrecorded debt. The community is actively debating the credibility of the reportnoting the firm's history of short-covering immediately after publicationwhile finding confidence in CEO Anthony Notos aggressive share purchases and the company's formal rebuttal and threat of legal action.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

Market sentiment for the QQQ remains highly volatile as traders grapple with a combination of regional conflict in the Middle East, rising oil prices, and intense anticipation ahead of the Federal Reserve's policy decision. The community is actively debating the sustainability of current price levels, with many traders expressing skepticism about the market's resilience and cautioning that current index strength may be an artificial result of heavy options activity and institutional positioning.

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Compute and Networking Business Unit (CNBU), Mobile Business Unit (MBU), Embedded Business Unit (EBU), and Storage Business Unit (SBU). The CNBU segment includes memory products and solutions sold into client, cloud server, enterprise, graphics, and networking markets. The MBU segment is involved in memory and storage products sold into smartphone and other mobile-device markets. The EBU segment focuses on memory and storage products sold into automotive, industrial, and consumer Markets. The SBU segment consists of SSDs and component-level solutions sold into enterprise and cloud, client, and consumer storage markets. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron Technology is seeing intense investor focus as it begins volume shipments of HBM4 memory for Nvidia's Vera Rubin platform ahead of its earnings report. The community is actively debating whether the stock's massive year-to-date rally is justified by long-term AI-driven memory demand or if a post-earnings pullback is inevitable due to profit-taking and elevated expectations.

Bitcoin is the world's first decentralized cryptocurrency, created in 2009 by the pseudonymous Satoshi Nakamoto. It enables peer-to-peer electronic cash transactions without intermediaries like banks or governments, operating on a blockchain secured by Proof of Work mining and the SHA-256 cryptographic algorithm.   With a fixed supply cap of 21 million coins and programmatic halvings every four years that reduce miner rewards, Bitcoin is designed as a deflationary digital asset often called "digital gold." Its value stems from solving the double-spending problem without trusted intermediaries, creating the first truly scarce digital asset with censorship resistance and permissionless access that no government, corporation, or individual can control.  Bitcoin operates as a decentralized peer-to-peer network where transactions are recorded on a public ledger called the blockchain, distributed across thousands of computers globally. Transactions are grouped into blocks added approximately every 10 minutes through mining, where specialized computers compete to solve complex mathematical puzzles.   Bitcoin has achieved mainstream adoption through multiple vectors. The January 2024 SEC approval of 11 spot Bitcoin ETFs opened Bitcoin investment to traditional finance participants, and corporations like Strategy (formerly MicroStrategy) are using Bitcoin as a treasury reserve asset to protect against currency debasement, offering MSTR holders amplified exposure to Bitcoin.   The Bitcoin ecosystem continues to evolve with innovations like Ordinals, which emerged in January 2023 to enable NFT-like functionality directly on Bitcoin, and BRC-20 tokens, an experimental standard for creating fungible tokens using Ordinal inscriptions. BTCFi (Bitcoin Finance) represents emerging financial applications extending beyond Bitcoin's traditional role, with protocols like Babylon allowing Bitcoin holders to stake BTC to secure Proof of Stake chains.

Bitcoin

Bitcoin is experiencing heightened volatility as institutional inflows through spot ETFs battle against bearish sentiment driven by PPI data and a hawkish Fed outlook. The community is sharply divided, with bulls pointing to resilient institutional demand and supply constraints while bears focus on macro risks and technical signals suggesting a potential pullback.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

DJT is facing heavy volatility and intense online debate as shareholders and political observers react to the administration's ongoing military engagement in Iran and a series of high-level resignations. Community discourse is sharply divided, with critics citing economic strain and geopolitical instability while supporters defend the administration's policy, all amidst broader concerns regarding inflation and the stock's long-term viability.

SPDR Gold Trust - SPDR Gold Shares

SPDR Gold Shares ETF

SPDR Gold Shares (GLD) is trending as investors grapple with conflicting signals from escalating geopolitical tensions in the Middle East and a strengthening U.S. dollar that is currently pressuring precious metals. While some market participants view gold as a necessary hedge against systemic debt and inflation, others are actively debating whether the metal is losing its traditional safe-haven status as institutional flow patterns and technical charts show significant volatility and divergent sentiment.

Swarmer, Inc. is an AI-driven software company, which develops software platforms and AI systems for autonomous swarm control of drones and unmanned vehicles. The firm offers STYX AI Command and Control System, MINAS Autonomy and Collaboration AI, and TRIDENT Embedded Drone Operating System. The company was founded by Alex Fink and Serhii Kuprienko in May 2023 and is headquartered in Austin, TX.

Swarmer Inc.

Swarmer Inc. is drawing significant attention following its debut as a low-float IPO, with the community actively debating whether its drone-focused defense technology justifies the rapid volatility or if it mirrors previous high-hype market cycles. Traders are closely monitoring the stock for momentum-driven swings, fueled by discussions around potential government contracts and the company's battle-tested software narrative.

One Stop Systems, Inc. engages in the design, manufacture, and marketing of computing modules and systems targeting edge deployments. It deals with the design and manufacture of high-performance customized computer and flash arrays, in-flight entertainment, and connectivity and value-added reseller with minimal customization. It operates through the OSS and OSS Europe segments. The company was founded by Stephen D. Cooper and Mark Gunn in 1998 and is headquartered in Escondido, CA.

One Stop Systems Inc

One Stop Systems is seeing strong community interest as investors weigh its pivot toward high-margin rugged AI edge computing against its role as a specialized defense supplier. While some traders are focused on short-term volatility and potential short squeeze dynamics, many long-term holders are highlighting its role in critical Navy programs and the potential for a valuation re-rate as it secures new commercial robotics and defense-adjacent contracts.

Sandisk Corp. engages in the development, manufacture, and provision of storage devices and solutions based on NAND flash technology. Its products include solid state drives, memory cards, and USB flash drives. The company was founded on February 5, 2024 and is headquartered in Milpitas, CA.

Sandisk Corp

Sandisk Corp is currently experiencing a massive surge driven by intense demand for NAND flash memory within AI data center infrastructure and a broader multi-year supply shortage. The community is actively debating whether this parabolic momentum is a sustainable long-term super-cycle or an overextended bubble primed for a significant rug pull, with many traders closely monitoring Micron's upcoming earnings as a potential catalyst for further volatility.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

MacroGenics (NASDAQ:MGNX) Upgraded to "Hold" at Wall Street Zen

Wall Street Zen raised MacroGenics from a "sell" rating to a "hold" rating in a report on Saturday...

<ul class="summary-bullets"><li>Barclays sees the company's antibody-drug conjugate data in 2026 as a potential source of upside.</li><li>MacroGenics CEO Eric Risser said on Monday that the company anticipates several important milestones in 2026, including initial clinical data from the early-stage studies of antibody drug conjugates MGC026 and MGC028.&nbsp;</li><li>The company also seeks to submit an application seeking clearance to start clinical trials for its other ADC MGC030 in the third quarter of 2026.</li></ul> Barclays on Tuesday raised the firm's price target on MacroGenics on optimism regarding its pipeline of targeted cancer therapies.Barclays increased the price target on MacroGenics (MGNX) to $4 from $3 and kept an ‘Overweight’ rating on the shares following the company’s Q4 report on Monday. The firm sees the company's antibody-drug conjugate data in 2026 as a potential source of upside.<h2 class="st-heading-2">Pipeline Updates</h2>MacroGenics CEO Eric Risser said on Monday that the company anticipates several important milestones in 2026, including initial clinical data from the early-stage studies of antibody drug conjugates MGC026 and MGC028, and from a study of its other experimental drug lorigerlimab.The company also seeks to submit an application seeking clearance to start clinical trials for its other ADC MGC030 in the third quarter of 2026, Risser said.Antibody-drug conjugates (ADCs) are targeted cancer therapies that deliver chemotherapy directly to cancer cells, minimizing damage to healthy tissue. Both Macrogenics’ MGC026 and MGC028 have demonstrated acceptable safety profiles to date as well as encouraging early evidence of anti-tumor activity. The company now anticipates reporting MGC026 clinical data in mid-2026, and MGC028 clinical data in the second half of 2026.Meanwhile, the U.S. Food and Drug Administration has placed a partial clinical hold on the company’s study evaluating lorigerlimab in patients with either platinum-resistant ovarian cancer (PROC) or clear cell gynecologic cancer (CCGC). The company said that it is working closely with the agency to resolve the hold “as soon as possible” and anticipates a clinical update in mid-2026.The company ended the year with cash, cash equivalents and marketable securities of $189.9 million, which it expects to support its cash runway into late 2027.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around MGNX stock stayed within the ‘extremely bullish’ territory over the past 24 hours, while message volume increased from ‘high’ to ‘extremely high’ levels.<a href="https://stocktwits.com/symbol/MGNX">MGNX stock</a> has gained more than 50% over the past 12 months.Read More: <a href="https://stocktwits.com/news-articles/markets/equity/viking-ceo-sees-its-obesity-drug-beating-novo-wegovy-in-weight-loss/cZdozzNRI7l">Viking CEO Sees Its Obesity Drug Beating Novo's Wegovy In Weight Loss</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

MGNX Closes Up 45% On Wall Street Optimism For Experimental Cancer Therapies

Barclays increased the price target on the stock to $4 from $3 and kept an ‘Overweight’ rating on the shares. 

Equity

Barclays increased the price target on the stock to $4 from $3 and kept an ‘Overweight’ rating on the shares. 


Barclays Forecasts Strong Price Appreciation for MacroGenics (NASDAQ:MGNX) Stock

Barclays increased their price target on MacroGenics from $3.00 to $4.00 and gave the company an "overweight" rating in a research report on Tuesday...

MacroGenics (NASDAQ:MGNX) Announces Quarterly Earnings Results, Beats Estimates By $0.20 EPS

MacroGenics (NASDAQ:MGNX - Get Free Report) announced its earnings results on Monday. The biopharmaceutical company reported ($0.22) EPS for the quarter, beating analysts' consensus estimates of...

MacroGenics (MGNX) Reports Q4 Loss, Tops Revenue Estimates

MacroGenics (MGNX) delivered earnings and revenue surprises of +47.31% and +71.24%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

BioLife Solutions, Inc. (BLFS) Surpasses Q4 Earnings and Revenue Estimates

BioLife Solutions (BLFS) delivered earnings and revenue surprises of +300.00% and +5.16%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

MacroGenics, Inc. (NASDAQ:MGNX) Receives Consensus Recommendation of "Hold" from Analysts

MacroGenics, Inc. (NASDAQ:MGNX - Get Free Report) has been given a consensus rating of "Hold" by the seven ratings firms that are covering the firm, Marketbeat reports. One investment analyst has...

MacroGenics (NASDAQ:MGNX) Stock Crosses Below 200-Day Moving Average - Should You Sell?

MacroGenics (NASDAQ:MGNX) Shares Pass Below 200 Day Moving Average - Here's What Happened...

MacroGenics, Inc. (NASDAQ:MGNX) Given Average Rating of "Hold" by Analysts

Shares of MacroGenics, Inc. (NASDAQ:MGNX - Get Free Report) have received an average recommendation of "Hold" from the seven ratings firms that are covering the firm, MarketBeat reports. One equities...

Sanofi's Teizeild Gets EU Approval for Treating Type 1 Diabetes

SNY wins EU approval for Teizeild, the first disease-modifying drug to delay stage 3 type 1 diabetes in adults and children aged eight and older.

MacroGenics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of antibody-based therapeutics for the treatment of cancer. Its product pipeline includes Margetuximab, Flotetuzumab, Retifanlimab, Enoblituzumab, Tebotelimab, MGC018, MGD019, IMGC936, and MGD014 for infectious diseases. The company was founded by Scott E. Koenig, Jeffrey V. Ravetch, LeRoy E. Hood, Ruedi Aebersold, and Alan Aderem on August 14, 2000 and is headquartered in Rockville, MD.

Current Price	$3.08
Prev Close	$3.10
Open	$3.12
Dividend Yield	0.00%
50-Day Moving Average	$1.98
Beta	1.45
Avg. Volume	606,280.29
PE Ratio	-2.60

52-Week High	$3.54
52-Week Low	$0.9896
Market Capitalization	$195.75M
EPS (Annual)	-$1.18
Price to Book	3.51
Revenue Per Employee	$510,238.91

MGNX
Macrogenics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest MGNX News

MGNXMacrogenics Inc